{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:20:34Z","timestamp":1773789634501,"version":"3.50.1"},"reference-count":43,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej13-0060","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T22:57:39Z","timestamp":1369868259000},"page":"967-976","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension"],"prefix":"10.1507","volume":"60","author":[{"given":"Kunitaka","family":"Murase","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Nagaishi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Takenoshita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nomiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Akehi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Yanase","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, et al. (2011) Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. <i>Endocr J<\/i> 58: 711-721.","DOI":"10.1507\/endocrj.EJ11-0133"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nishikawa T, Omura M, Saito J, Matsuzawa Y (2012) Primary aldosteronism: comparison between guidelines of the Japanese and the US Endocrine Society. <i>Expert Rev Endocrinol Metab<\/i> 7: 637-645.","DOI":"10.1586\/eem.12.65"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. <i>Hypertens Res<\/i> 27:193-202.","DOI":"10.1291\/hypres.27.193"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Porteri E, et al. (2006) prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. <i>J Am Coll Cardiol<\/i> 48: 2293-2300.","DOI":"10.1016\/j.jacc.2006.07.059"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA (1993) Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. <i>Clin Exp Pharmacol Physiol<\/i> 20: 296-298.","DOI":"10.1111\/j.1440-1681.1993.tb01687.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, et al. (2010) Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn\u2019s Registry. <i>Horm Metab Res<\/i> 42: 435-439.","DOI":"10.1055\/s-0029-1246189"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Strauch B, Widimsk&yacute; J, Sindelka G, Skrha J (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? <i>Physiol Res<\/i> 52: 503-506.","DOI":"10.33549\/physiolres.930298"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Corry DB, Tuck ML (2003) The effect of aldosterone on glucose metabolism. <i>Curr Hypertens Rep<\/i> 5: 106-109.","DOI":"10.1007\/s11906-003-0065-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. <i>Diabetologia<\/i> 29: 119-121.","DOI":"10.1007\/BF00456122"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, et al. (2009) Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substate (IRS)1 and IRS2 via a reactive oygen species-mediated pathway in 3T3-L1 adipocytes. <i>Endocrinology<\/i> 150: 1662-1669.","DOI":"10.1210\/en.2008-1018"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Iimura O (1996) Insulin resistance and hypertension in Japanese. <i>Hypertension Res<\/i> 19 suppl 1: S1-8.","DOI":"10.1291\/hypres.19.SupplementI_S1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. <i>Hypertension<\/i> 37: 1053-1059.","DOI":"10.1161\/01.HYP.37.4.1053"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. DeFronzo RA (1981) The effect of insulin on renal sodium metabolism. A review with clinical implications. <i>Diabetologia<\/i> 21: 165-171.","DOI":"10.1007\/BF00252649"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. <i>J Clin Invest<\/i> 87: 2246-2252.","DOI":"10.1172\/JCI115260"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Umpierrez GE, Cantey P, Smiley D (2007) Primary aldosteronism in diabetic subjects with resistant hypertension. <i>Diabetes Care<\/i> 30: 1699-1703.","DOI":"10.2337\/dc07-0031"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mukherjee JJ, Khoo CM, Thai AC (2010) Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. <i>Diab Vasc Dis Res<\/i> 7: 6-11.","DOI":"10.1177\/1479164109350556"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li N, Wang M, Wang H, Zhang D, Wang X, et al. (2013) Prevalence of primary aldosteronism in hypertensive subjects with hyperglycemia. <i>Clin Exp Hypertens<\/i> 35: 175-182.","DOI":"10.3109\/10641963.2012.712175"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). <i>Hypertens Res <\/i>32: 3-107<i>.<\/i>","DOI":"10.1038\/hr.2009.34"},{"key":"19","unstructured":"19. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. (2012) Committee report on the classification and the diagnostic criteria of diabetes mellitus. Diabetes (Tounyoubyo) 55: 485-504 (In Japanese)."},{"key":"20","unstructured":"20. Omura M, Nishikawa T (2006) Screening tests and diagnostic examinations of hypertension for primary aldosteronism. <i>Rinsho Byori <\/i>54: 1157-1163 (In Japanese)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sonoyama T, Sone M, Miyashita K, Tamura N, Yamahara K, et al. (2011) Significance of adrenocorticotropin stimulation test in the diagnosis of an aldosterone-producing adenoma. <i>J Clin Endocrinol Metab <\/i>96: 2771-2778.","DOI":"10.1210\/jc.2011-0573"},{"key":"22","unstructured":"22. Akehi Y, Murase K, Nagaishi R, Takenoshita H, Nomiyama T, et al. (2011) The current state and problems of adrenal venous sampling in Fukuoka University Hospital. <i>Clinical Endocrinol (Tokyo)<\/i> 59: 651-655 (In Japanese)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, et al. (2004) Role for adrenal venous sampling in primary aldosteronism. <i>Surgery<\/i> 136:1227-1235.","DOI":"10.1016\/j.surg.2004.06.051"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kintscher U, Foryst-Ludwig A, Unger T (2008) Inhibiting angiotensin type 1 receptors as a target for diabetes.<i> Expert Opin Ther Targets<\/i> 12: 1257-1263.","DOI":"10.1517\/14728222.12.10.1257"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Givertz MM (2001) Manipulation of the renin-angiotensin system. <i>Circulation <\/i>104: E14-E18.","DOI":"10.1161\/hc3001.094733"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rita OD, Hackam DG, Spence JD (2012) Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. <i>Can J Cardiol<\/i> 28: 706-711.","DOI":"10.1016\/j.cjca.2012.04.014"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Stowasser M (2009) Update in primary aldosteronism. <i>J Clin Endocrinol Metab<\/i> 94: 3623-3630.","DOI":"10.1210\/jc.2009-1399"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Queisser N, Schupp N (2012) Aldosterone, oxidative stress, and NF-&kappa;B activation in hypertension-related cardiovascular and renal diseases. <i>Free Radic Biol Med <\/i>53: 314-327.","DOI":"10.1016\/j.freeradbiomed.2012.05.011"},{"key":"29","unstructured":"29. Hillaert MA, Lentjes EG, Kemperman H, van der Graaf Y, Nathoe HM, et al. (2012) Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. <i>Int J Cardio <\/i>2012 Jun 22 [Epub ahead of print]."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med<\/i> 341: 709-717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nishikawa T, Saito J, Omura M (2007) Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? <i>Endocr J<\/i> 54: 487-495.","DOI":"10.1507\/endocrj.KR-105"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. (2008) Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opin Pharmacother<\/i> 9: 509-515.","DOI":"10.1517\/14656566.9.4.509"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, et al. (2008) A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. <i>Hypertension <\/i>51: 742-748.","DOI":"10.1161\/HYPERTENSIONAHA.107.103580"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hajjar I, Kotchen TA (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. <i>JAMA<\/i> 290: 199-206.","DOI":"10.1001\/jama.290.2.199"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. <i>Am J Hypertens <\/i>16: 925-930.","DOI":"10.1016\/S0895-7061(03)01032-X"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. <i>J Clin Endocrinol Metab <\/i>91: 454-459.","DOI":"10.1210\/jc.2005-1733"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Schwartz GL, Turner ST (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. <i>Clin Chem<\/i> 51: 386-394.","DOI":"10.1373\/clinchem.2004.041780"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, et al. (2011) Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. <i>J Mol Endocrinol<\/i> 46: 37-39.","DOI":"10.1677\/JME-10-0088"},{"key":"39","unstructured":"39. Kuris S, Iwasaki T, Mitsuba N, Ishibashi K, Dohi Y, et al. (2012) Impact of electrocardiographic findings for diagnosis of left ventricular hypertrophy in patients with primary aldosteronism. <i>J Renin Angiotensin Aldosterone Syst <\/i>14: 51-55."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Skov J, Dejgaard A, Fr&oslash;ki&aelig;r J, Holst JJ, Jonassen T, et al. (2013) Glucagon-Like Peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. <i>J Clin Endocrinol Metab <\/i>98: E664-671.","DOI":"10.1210\/jc.2012-3855"},{"key":"41","unstructured":"41. Ralph AD (1980) Hyperkalemia and hyporeninemic hypoaldosteronism. <i>Kidney Int <\/i>17: 118-134."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Young WF (2007) Primary aldosteronism:renaissance of a syndrome. <i>Clin Endocrinol (Oxf)<\/i> 66: 607-618.","DOI":"10.1111\/j.1365-2265.2007.02775.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, et al. (2013) Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. <i>J Steroid Biochem Mol Biol <\/i>2013 Feb 28 [Epub ahead of print].","DOI":"10.1016\/j.jsbmb.2013.02.012"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/8\/60_EJ13-0060\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T09:31:28Z","timestamp":1715419888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/8\/60_EJ13-0060\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0060","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}